DOCSLIB.ORG

030320 the Chromogranin–Secretogranin Family

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
030320 the Chromogranin–Secretogranin Family The new england journal of medicine review article mechanisms of disease The Chromogranin–Secretogranin Family Laurent Taupenot, Ph.D., Kimberly L. Harper, M.D., and Daniel T. O’Connor, M.D. From the Department of Medicine (L.T., eurons and neuroendocrine cells contain membrane- K.L.H., D.T.O.) and the Center for Molecular delimited pools of peptide hormones, biogenic amines, and neurotransmit- Genetics (D.T.O.), University of California n at San Diego, La Jolla; and the Veterans ters with a characteristic electron-dense appearance on transmission electron Affairs San Diego Healthcare System, San microscopy (Fig. 1). These vesicles, which are present throughout the neuroendocrine Diego, Calif. (L.T., K.L.H., D.T.O.). Address system1,2 and in a variety of neurons, store and release chromogranins and secretogranins reprint requests to Dr. O’Connor at the 3,4 Department of Medicine (9111H), Univer- (also known as “granins”), a unique group of acidic, soluble secretory proteins. The sity of California at San Diego, 3350 La Jolla three “classic” granins are chromogranin A, which was first isolated from chromaffin Village Dr., San Diego, CA 92161, or at cells of the adrenal medulla5,6; chromogranin B, initially characterized in a rat pheochro- [email protected]. mocytoma cell line7; and secretogranin II (sometimes called chromogranin C), which 8,9 N Engl J Med 2003;348:1134-49. was originally described in the anterior pituitary. Four other acidic secretory pro- Copyright © 2003 Massachusetts Medical Society. teins were later proposed for membership in the granin family10: secretogranin III (or 1B1075),11 secretogranin IV (or HISL-19),12 secretogranin V (or 7B2),13 and secretogra- nin VI (or NESP55).14 In this article, we review aspects of the structures, biochemical properties, and clin- ical importance of granins, with particular emphasis on chromogranin A, the granin that was discovered first and that has been studied most extensively. We discuss how granins contribute to the formation of secretory granules and how, as prohormones, they give rise to bioactive peptides through proteolytic processing. Because of their ubiquitous distribution in neuroendocrine and nervous-system tissues and their cose- cretion with resident peptide hormones and biogenic amines, granins are valuable in- dicators of sympathoadrenal activity and clinically useful markers of secretion from normal and neoplastic neuroendocrine cells.1,15-17 Indeed, numerous studies have doc- umented the clinical value of detecting granins in tissues and measuring circulating levels of granins, particularly chromogranin A. In addition to providing information about the neuroendocrine character of various neoplasms, measurement of chromo- granin A has yielded insights into the pathogenesis of essential hypertension. molecular and genetic aspects of granins structural and physicochemical properties Granins consist of single-polypeptide chains of approximately 180 to 700 amino acid residues, bearing an amino-terminal signal peptide that directs the movement of the preproteins from ribosomes to the endoplasmic reticular lumen and, hence, the Golgi complex, where further post-translational modifications occur. Granins tend to bind calcium with low affinity but high capacity and then aggregate in vitro at low pH in the presence of calcium.18-24 These aggregation characteristics suggest that granins have functions within the core of secretory granules. genomic organization and transcriptional regulation The chromosomal positions of all granins except secretogranin IV have been determined in humans, cows, mice, and rats (Table 1); in each case, the loci lie in regions of locally 1134 n engl j med 348;12 www.nejm.org march 20, 2003 Downloaded from www.nejm.org by RODRIGUEZ POVEDA AIXA MILDRED on May 16, 2010 . Copyright © 2003 Massachusetts Medical Society. All rights reserved. mechanisms of disease conserved gene order in homologous chromo- somes (Fig. 2).25 A pH The distribution of granins throughout the neu- 5.8 5.4 5.0 4.6 4.2 roendocrine system has been studied with Northern blot analysis of messenger RNA. Granin messages CgB have been found in cells of various neuroendocrine DBH CgA tissues that have a regulated secretory pathway.9,26,27 97 Moreover, granin synthesis responds differently in different cell types to agents that elevate cyclic 66 AMP (cAMP), steroid hormones, neurotrophins, and phorbol ester. Experiments with transfected granin-gene pro- 45 moters have clarified the mechanism of constitutive and secretagogue-inducible expression of granins in specific cells.28 The proximal promoter regions of chromogranin A, chromogranin B, and secreto- 24 granin II contain a functional cAMP-response ele- Molecular Mass (kD) ment (CRE) upstream of a TATA box (a region of seven nucleotides, mainly thymidine and adenine, located upstream of the starting point of transcrip- 18 tion); otherwise, their promoter sequences dif- fer.29,30 The specificity of expression of chromo- granin A, chromogranin B, and secretogranin III in mouse neuroendocrine cells has been mapped to the CRE site.30-32 Upstream promoter elements may also be important in cell-specific expression of hu- B C man chromogranin A and secretogranin II.33,34 These CRE sites may explain how the expression of chromogranin A, chromogranin B, and secreto- granin II is up-regulated in neuroendocrine cells by nicotinic–cholinergic agonists and the pregangli- onic neuropeptide pituitary adenylyl cyclase–acti- vating polypeptide.31,32,35,36 Moreover, neuronal differentiation of a pheochromocytoma cell line 100 nm 5 mm (PC12) induced by neurotrophin nerve growth fac- tor up-regulates expression of the genes for chro- mogranin A and chromogranin B through an effect Figure 1. Localization of Chromogranins with Dense-Core Secretory Granules on the CRE site.31,37 of Sympathoadrenal Chromaffin Cells. An upstream serum response element also has Panel A shows soluble-core proteins in bovine chromaffin vesicles after two- an important role in the expression of the mouse dimensional sodium dodecyl sulfate–polyacrylamide gel electrophoresis, fol- 32 lowed by Coomassie blue staining. DBH denotes dopamine b-hydroxylase, CgA secretogranin II gene, and a proximal G- or chromogranin A, and CgB chromogranin B. Panel B shows an electron micro- C-rich region contributes to the expression of the graph of bovine chromaffin cells. The electron-dense spherical and oblong struc- mouse chromogranin B gene.31 Glucocorticoid tures are dense-core secretory chromaffin granules. The black particles, which have a diameter of 8 to 12 nm, represent immunogold labeling of chromogranin sensitivity has been mapped to a novel glucocorti- A with rabbit antibovine chromogranin A antibody. Panel C shows the subcellular coid-response-element variant in the rat chromo- distribution of a human chromogranin A–enhanced green fluorescent protein granin A.38 (EGFP) chimeric photoprotein, in living sympathoadrenal PC12 cells. Chromo- granin A–EGFP expression was examined by three-dimensional deconvolution microscopy. Nuclei were visualized with blue dye (Hoechst 33342). Optical sec- sorting mechanisms tions along the z axis were acquired with increments of 200 nm and the use of Proteins are secreted from cells by exocytosis in ei- a 100¬ oil-immersion objective to generate three-dimensional views of the ther a constitutive or a regulated manner.39,40 The photoprotein distribution. Chromogranin A–EGFP displays a bright, punctate or vesicular fluorescence signal, especially within the subplasmalemmal re- rate of secretion through the constitutive pathway, gion, indicating storage of the chimera in chromaffin secretory granules. which operates in every type of cell, is a simple func- n engl j med 348;12 www.nejm.org march 20, 2003 1135 Downloaded from www.nejm.org by RODRIGUEZ POVEDA AIXA MILDRED on May 16, 2010 . Copyright © 2003 Massachusetts Medical Society. All rights reserved. The new england journal of medicine Table 1. Physicochemical Properties of Granins.* SgIII SgIV SgV SgVI Property CgA CgB SgII (1B1075) (HISL-19) (7B2) (NESP55) Chromosome localization 14 (human), 20 (human), 2 (human), 2 (mouse) ND 15 (human), 20 (human) 21 (bovine), 3 (rat), 9 (rat), 2 (mouse) 6 (rat), 2 (mouse) 1 (mouse) 12 (mouse) Amino acid residues† 431–445 626–657 559–586 449–507 ND 185 241 Molecular mass (kD)‡ Calculated 49–52 48–52 67.5 51–57 ND 21 27.5 Apparent 74–80 100–120 86 57 35 23 55 Acidic residues (%) 25 24 20 19 ND 16 21 Isoelectric point (pHi) 4.5–5.0 5.1–5.2 5.0 5.1 5.6 5.2 4.4–5.2 Multibasic sites§ 8–10 15–18 9 6–10 ND 3 5 Disulfide-bonded loop Yes Yes No No ND No No Calcium binding Yes Yes Yes ND ND Yes ND Thermostability Yes Yes Yes ND ND Yes Yes Phosphorylation Yes Yes Yes ND ND Yes Yes Sulfation Yes Yes Yes Yes ND Yes ND O-glycosylation Yes Yes Yes ND ND ND Yes N-glycosylation No Yes No No No No No Phosphorylation Yes Yes Yes ND ND Yes Yes * CgA denotes chromogranin A, CgB chromogranin B, SgII secretogranin II, SgIII secretogranin III, SgIV secretogranin IV, SgV secretogranin V, SgVI secretogranin VI, and ND not determined. † Amino acid residues are for mature protein without signal peptide. ‡ The molecular mass was calculated from the primary structure. The apparent molecular mass was determined with the use of sodium dodecyl sulfate–polyacrylamide-gel electrophoresis. § Multibasic sites refers to sites with two or more consecutive Arg or Lys residues. tion of the rate of synthesis of the secreted sub- nonretained proteins.41 The mechanism by which stance. In this pathway, newly synthesized proteins granins are sorted at the trans-Golgi network to en- (e.g., albumin and immunoglobulins) continuous- ter the regulated pathway of secretion is unclear.41-48 ly pass through to the trans-Golgi network and are Selective aggregation of regulated secretory then transported in constitutive vesicles to the plas- proteins at the level of the trans-Golgi network ma membrane for immediate release.
Load more

Recommended publications
  • Uncorrected Author Proof Boller Et Al
    Journal of Parkinson’s Disease xx (2020) x–xx 1 DOI 10.3233/JPD-202323 IOS Press 1 Review 2 Neuropathological and Biomarker Findings 3 in Parkinson’s Disease and Alzheimer’s 4 Disease: From Protein Aggregates to 5 Synaptic Dysfunction a,b,∗ c,d,e,∗ 6 Yaroslau Compta and Tamas Revesz a 7 Parkinson’s disease & Movement Disorders Unit, Neurology Service, Hospital Cl´ınic / IDIBAPS / CIBERNED, 8 Barcelona, Catalonia, Spain b 9 Institut de Neuroci`encies, Maextu’s excellence center, University of Barcelona, Barcelona, Catalonia, Spain c 10 Queen Square Brain Bank for Neurological Disorders, Department of Clinical and Movement Neurosciences, 11 UCL Queen Square Institute of Neurology, University College London, UK d 12 Reta Lila Weston Institute of Neurological Studies, UCL Institute of Neurology, London, UK 13 eDepartment of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College 14 London, UK Accepted 9 November 2020 15 Abstract. 16 There is mounting evidence that Parkinson’s disease (PD) and Alzheimer’s disease (AD) share neuropathological hallmarks, 17 while similar types of biomarkers are being applied to both. In this review we aimed to explore similarities and differences 18 between PD and AD at both the neuropathology and the biomarker levels, specifically focusing on protein aggregates 19 and synapse dysfunction. Thus, amyloid-␤ peptide (A␤) and tau lesions of the Alzheimer-type are common in PD and 20 ␣-synuclein Lewy-type aggregates are frequent findings in AD. Modern neuropathological techniques adding to routine 21 immunohistochemistry might take further our knowledge of these diseases beyond protein aggregates and down to their 22 presynaptic and postsynaptic terminals, with potential mechanistic and even future therapeutic implications.
    [Show full text]
  • Limited Diagnostic Utility of Chromogranin a Measurements in Workup of Neuroendocrine Tumors
    diagnostics Article Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors Jonas Baekdal 1,2,*, Jesper Krogh 1,2, Marianne Klose 1,2, Pernille Holmager 1,2, Seppo W. Langer 1,3, Peter Oturai 1,4,5, Andreas Kjaer 1,4,5 , Birgitte Federspiel 1,6, Linda Hilsted 1,7, Jens F. Rehfeld 1,7, Ulrich Knigge 1,2,8 and Mikkel Andreassen 1,2 1 ENETS Neuroendocrine Tumor Centre of Excellence, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark; [email protected] (J.K.); [email protected] (M.K.); [email protected] (P.H.); [email protected] (S.W.L.); [email protected] (P.O.); [email protected] (A.K.); [email protected] (B.F.); [email protected] (L.H.); [email protected] (J.F.R.); [email protected] (U.K.); [email protected] (M.A.) 2 Department of Endocrinology, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark 3 Department of Oncology, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark 4 Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Copenhagen University Hospital, 2100 Copenhagen, Denmark 5 Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, 2100 Copenhagen, Denmark 6 Department of Pathology, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark 7 Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark 8 Department of Surgery and Transplantation, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark * Correspondence: [email protected]; Tel.: +45-6013-4687 Received: 11 October 2020; Accepted: 28 October 2020; Published: 29 October 2020 Abstract: Background: Plasma chromogranin A (CgA) is related to tumor burden and recommended in the follow-up of patients diagnosed with neuroendocrine tumors (NETs).
    [Show full text]
  • Small-Cell Neuroendocrine Tumors: Cell State Trumps the Oncogenic Driver Matthew G
    Published OnlineFirst January 26, 2018; DOI: 10.1158/1078-0432.CCR-17-3646 CCR Translations Clinical Cancer Research Small-Cell Neuroendocrine Tumors: Cell State Trumps the Oncogenic Driver Matthew G. Oser1,2 and Pasi A. Janne€ 1,2,3 Small-cell neuroendocrine cancers often originate in the lung SCCB and SCLC share common genetic driver mutations. but can also arise in the bladder or prostate. Phenotypically, Clin Cancer Res; 24(8); 1775–6. Ó2018 AACR. small-cell carcinoma of the bladder (SCCB) shares many simi- See related article by Chang et al., p. 1965 larities with small-cell lung cancer (SCLC). It is unknown whether In this issue of Clinical Cancer Research, Chang and colleagues ponent, suggesting that RB1 and TP53 loss occurs after the initial (1) perform DNA sequencing to characterize the mutational development of the urothelial carcinoma and is required for signature of small-cell carcinoma of the bladder (SCCB). They transdifferentiation from urothelial cancer to SCCB. This is rem- find that both SCCB and small-cell lung cancer (SCLC) harbor iniscent of a similar phenomenon observed in two other tumors near universal loss-of-function mutations in RB1 and TP53.In types: (i) EGFR-mutant lung cancer and (ii) castration-resistant contrast to the smoking mutational signature found in SCLC, prostate cancer, where RB1 and TP53 loss is necessary for the SCCB has an APOBEC mutational signature, a signature also transdifferentiation from an adenocarcinoma to a small-cell neu- found in urothelial carcinoma. Furthermore, they show that SCCB roendocrine tumor. EGFR-mutant lung cancers acquire RB1 loss as and urothelial carcinoma share many common mutations that are a mechanism of resistance to EGFR tyrosine kinase inhibitors (3), distinct from mutations found in SCLC, suggesting that SCCB and castration-resistant prostate cancers acquire RB1 and TP53 may arise from a preexisting urothelial cancer.
    [Show full text]
  • Chromogranin a Regulation of Obesity and Peripheral Insulin Sensitivity
    MINI REVIEW published: 08 February 2017 doi: 10.3389/fendo.2017.00020 Chromogranin A Regulation of Obesity and Peripheral Insulin Sensitivity Gautam K. Bandyopadhyay1 and Sushil K. Mahata1,2* 1 Department of Medicine, University of California San Diego, La Jolla, CA, USA, 2 Department of Medicine, Metabolic Physiology and Ultrastructural Biology Laboratory, VA San Diego Healthcare System, San Diego, CA, USA Chromogranin A (CgA) is a prohormone and granulogenic factor in endocrine and neuroendocrine tissues, as well as in neurons, and has a regulated secretory pathway. The intracellular functions of CgA include the initiation and regulation of dense-core granule biogenesis and sequestration of hormones in neuroendocrine cells. This protein is co-stored and co-released with secreted hormones. The extracellular functions of CgA include the generation of bioactive peptides, such as pancreastatin (PST), vaso- statin, WE14, catestatin (CST), and serpinin. CgA knockout mice (Chga-KO) display: (i) hypertension with increased plasma catecholamines, (ii) obesity, (iii) improved hepatic Edited by: insulin sensitivity, and (iv) muscle insulin resistance. These findings suggest that individual Gaetano Santulli, CgA-derived peptides may regulate different physiological functions. Indeed, additional Columbia University, USA studies have revealed that the pro-inflammatory PST influences insulin sensitivity and Reviewed by: Anne-Francoise Burnol, glucose tolerance, whereas CST alleviates adiposity and hypertension. This review will Institut national de la santé et de la focus on the different metabolic roles of PST and CST peptides in insulin-sensitive and recherche médicale, France Marialuisa Appetecchia, insulin-resistant models, and their potential use as therapeutic targets. Istituti Fisioterapici Ospitalieri (IRCCS), Italy Keywords: obesity, insulin resistance, inflammation, chromogranin A knockout, pancreastatin, catestatin Hiroki Mizukami, Hirosaki University, Japan *Correspondence: INTRODUCTION Sushil K.
    [Show full text]
  • Identification of VGF Nerve Growth Factor Inducible-Producing Cells In
    Int. J. Med. Sci. 2020, Vol. 17 480 Ivyspring International Publisher International Journal of Medical Sciences 2020; 17(4): 480-489. doi: 10.7150/ijms.39101 Research Paper Identification of VGF nerve growth factor inducible-producing cells in human spinal cords and expression change in patients with amyotrophic lateral sclerosis Yasuhiro Noda1, Miruto Tanaka1, Shinsuke Nakamura1, Junko Ito2, Akiyoshi Kakita2, Hideaki Hara1, and Masamitsu Shimazawa1 1. Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan. 2. Department of Pathology, Brain Research Institute, Niigata University, Niigata, Japan. Corresponding author: Dr. Masamitsu Shimazawa, Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan. E-mail: [email protected], Telephone and Fax: +81-58-230-8126 © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2019.08.06; Accepted: 2019.12.23; Published: 2020.02.04 Abstract Amyotrophic lateral sclerosis (ALS) is a serious disease characterized by the degeneration of motor neurons resulting in muscle weakness and paralysis. The neuroendocrine polypeptide VGF is localized in the central nervous system and peripheral endocrine neurons and is cleaved into several polypeptides with multiple functions. Previous studies revealed that VGF was decreased in the cerebrospinal fluid of ALS model mice and sporadic ALS patients. However, it is unknown which cells supply VGF in the spinal cord and a detailed localization is lacking.
    [Show full text]
  • The Chromogranin A-Derived Peptides Catestatin and Vasostatin in Dogs
    Höglund et al. Acta Vet Scand (2020) 62:43 https://doi.org/10.1186/s13028-020-00541-3 Acta Veterinaria Scandinavica RESEARCH Open Access The chromogranin A-derived peptides catestatin and vasostatin in dogs with myxomatous mitral valve disease Katja Höglund1* , Jens Häggström2 , Odd Viking Höglund2 , Mats Stridsberg3 , Anna Tidholm2,4 and Ingrid Ljungvall2 Abstract Background: The protein chromogranin A (CgA) is stored and co-released with catecholamines from the stimulated adrenal glands. Increased plasma concentrations of CgA have been shown in people with heart disease. The aim of the study was to investigate whether plasma concentrations of the CgA-derived biologically active peptides catesta- tin and vasostatin were associated with the severity of myxomatous mitral valve disease (MMVD) in dogs and to assess potential associations between these blood variables and dog characteristics, echocardiographic variables, heart rate (HR), blood pressure (BP) and plasma N-terminal-proBNP (NT-proBNP) concentration. Sixty-seven privately owned dogs with or without MMVD were included. The dogs underwent physical examination, blood pressure measurement, blood sample collection, and echocardiographic examination. Plasma concentrations of catestatin and vasostatin were analyzed using radioimmunoassay. Results: Catestatin concentration decreased with increasing left atrial and ventricular size (R 2 0.09, P 0.019), and increased with increasing systolic and diastolic blood pressures (R2 0.08, P 0.038). Regression≤ analyses≤ showed no signifcant associations for vasostatin. No diferences in plasma concentrations≤ ≤ of catestatin or vasostatin were found between the disease severity groups used in the study. Conclusions: In the present dog population, the catestatin concentration showed weak negative associations with left atrial and ventricular sizes, both of which are known to increase with increasing severity of MMVD.
    [Show full text]
  • Neurod1 Regulation of Migration Accompanies the Differential Sensitivity of Neuroendocrine Carcinomas to Trkb Inhibition
    OPEN Citation: Oncogenesis (2013) 2, e63; doi:10.1038/oncsis.2013.24 & 2013 Macmillan Publishers Limited All rights reserved 2157-9024/13 www.nature.com/oncsis ORIGINAL ARTICLE NeuroD1 regulation of migration accompanies the differential sensitivity of neuroendocrine carcinomas to TrkB inhibition JK Osborne1, JE Larsen2, JX Gonzales1, DS Shames2,4, M Sato2,5, II Wistuba3, L Girard1,2, JD Minna1,2 and MH Cobb1 The developmental transcription factor NeuroD1 is anomalously expressed in a subset of aggressive neuroendocrine tumors. Previously, we demonstrated that TrkB and neural cell adhesion molecule (NCAM) are downstream targets of NeuroD1 that contribute to the actions of neurogenic differentiation 1 (NeuroD1) in neuroendocrine lung. We found that several malignant melanoma and prostate cell lines express NeuroD1 and TrkB. Inhibition of TrkB activity decreased invasion in several neuroendocrine pigmented melanoma but not in prostate cell lines. We also found that loss of the tumor suppressor p53 increased NeuroD1 expression in normal human bronchial epithelial cells and cancer cells with neuroendocrine features. Although we found that a major mechanism of action of NeuroD1 is by the regulation of TrkB, effective targeting of TrkB to inhibit invasion may depend on the cell of origin. These findings suggest that NeuroD1 is a lineage-dependent oncogene acting through its downstream target, TrkB, across multiple cancer types, which may provide new insights into the pathogenesis of neuroendocrine cancers. Oncogenesis (2013) 2, e63; doi:10.1038/oncsis.2013.24; published online 19 August 2013 Subject Categories: Cellular oncogenes Keywords: NeuroD1; neuroendocrine; TrkB; migration INTRODUCTION increased expression of NeuroD1, possibly in a lineage-dependent Aberrant expression of basic helix loop helix transcription factors manner.
    [Show full text]
  • The Granin Protein Family in Cardiac Disease
    The granin protein family in cardiac disease Helge R. Røsjø, MD1,2,3 1 Division of Medicine, Akershus University Hospital, Lørenskog, Norway 2 Institute of Experimental Medical Research, Oslo University Hospital, Ullevål, Oslo, Norway 3 Center for Heart Failure Research and K.G. Jebsen Cardiac Research Centre, Institute of Clinical Medicine, University of Oslo, Oslo, Norway © Helge R. Røsjø, 2012 Series of dissertations submitted to the Faculty of Medicine, University of Oslo No. 1333 ISBN 978-82-8264-359-7 All rights reserved. No part of this publication may be reproduced or transmitted, in any form or by any means, without permission. Cover: Inger Sandved Anfinsen. Printed in Norway: AIT Oslo AS. Produced in co-operation with Unipub. The thesis is produced by Unipub merely in connection with the thesis defence. Kindly direct all inquiries regarding the thesis to the copyright holder or the unit which grants the doctorate. Contents Supported by ......................................................................................................................... 4 Acknowledgments ................................................................................................................ 5 Abbreviations ........................................................................................................................ 8 List of papers in thesis: ....................................................................................................... 10 Introduction .......................................................................................................................
    [Show full text]
  • Chromogranin a Dependent Upon Interaction with Biogenesis in Mast
    Secretogranin III Directs Secretory Vesicle Biogenesis in Mast Cells in a Manner Dependent upon Interaction with Chromogranin A This information is current as of October 4, 2021. Prerna Prasad, Angel A. Yanagihara, Andrea L. Small-Howard, Helen Turner and Alexander J. Stokes J Immunol 2008; 181:5024-5034; ; doi: 10.4049/jimmunol.181.7.5024 http://www.jimmunol.org/content/181/7/5024 Downloaded from References This article cites 42 articles, 15 of which you can access for free at: http://www.jimmunol.org/content/181/7/5024.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on October 4, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2008 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Secretogranin III Directs Secretory Vesicle Biogenesis in Mast Cells in a Manner Dependent upon Interaction with Chromogranin A1 Prerna Prasad,2*§ Angel A. Yanagihara,2‡ Andrea L. Small-Howard,2* Helen Turner,2,3*† and Alexander J.
    [Show full text]
  • Gastrointestinal Stromal Tumors Regularly Express Synaptic Vesicle Proteins: Evidence of a Neuroendocrine Phenotype
    Endocrine-Related Cancer (2007) 14 853–863 Gastrointestinal stromal tumors regularly express synaptic vesicle proteins: evidence of a neuroendocrine phenotype Per Bu¨mming, Ola Nilsson1,Ha˚kan Ahlman, Anna Welbencer1, Mattias K Andersson 1, Katarina Sjo¨lund and Bengt Nilsson Lundberg Laboratory for Cancer Research, Departments of Surgery and 1Pathology, Sahlgrenska Academy at the University of Go¨teborg, Sahlgrenska University Hospital, SE-413 45 Go¨teborg, Sweden (Correspondence should be addressed to O Nilsson; Email: [email protected]) Abstract Gastrointestinal stromal tumors (GISTs) are thought to originate from the interstitial cells of Cajal, which share many properties with neurons of the gastrointestinal tract. Recently, we demonstrated expression of the hormone ghrelin in GIST. The aim of the present study was therefore to evaluate a possible neuroendocrine phenotype of GIST. Specimens from 41 GISTs were examined for the expression of 12 different synaptic vesicle proteins. Expression of synaptic-like microvesicle proteins, e.g., Synaptic vesicle protein 2 (SV2), synaptobrevin, synapsin 1, and amphiphysin was demonstrated in a majority of GISTs by immunohistochemistry, western blotting, and quantitative reversetranscriptase PCR. One-third of the tumors also expressed the large dense core vesicle protein vesicular monoamine transporter 1. Presence of microvesicles and dense core vesicles in GIST was confirmed by electron microscopy. The expression of synaptic-like microvesicle proteins in GIST was not related to risk profile or to KIT/platelet derived growth factor alpha (PDGFRA) mutational status. Thus, GISTs regularly express a subset of synaptic-like microvesicle proteins necessary for the regulated secretion of neurotransmitters and hormones. Expression of synaptic-like micro-vesicle proteins, ghrelin and peptide hormone receptors in GIST indicate a neuroendocrine phenotype and suggest novel possibilities to treat therapy-resistant GIST.
    [Show full text]
  • Elevated Serum Chromogranin a Is Detectable in Patients with Carcinomas at Advanced Disease Stages
    Annals o f Clinical & Laboratory Science, vol. 30, no. 2, 2000 175 Elevated Serum Chromogranin A is Detectable in Patients with Carcinomas at Advanced Disease Stages James T. Wu,1 Alan J. Erickson,1 Kuo-Chien Tsao,2 Tsu-Lan Wu,2 and Chien-Feng Sun2 1 Department of Pathology, University of Utah School of Medicine, and Associated Regional University Pathologists (ARUP), University of Utah Health Sciences Center, Salt Lake City, Utah 2 Department of Clinical Pathology, Chang Gung Memorial Hospital, Taipei, Taiwan Abstract. Chromogranin A (CgA), a marker of neuroendocrine cells and an indicator for neuroendocrine differentiation, is associated with a poor prognosis when detected in tumor tissue, based on immunohistochemical techniques. We sought to determine whether it is possible to detect elevated serum CgA in patients with commonly occurring carcinomas of non-neuroendocrine origin. CgA was measured in both random and serial serum specimens, using a serum CgA assay developed in our laboratory. Elevated levels of serum CgA were detected in patients with carcinoma of the prostate, breast, ovary, pancreas, and colon. Serum CgA levels in patients with all types of carcinoma appeared to parallel the changes of serum dominant tumor markers and were found in sera containing highly elevated tumor markers. Based on these preliminary findings, perhaps we should monitor CgA, in addition to the routinely used tumor markers, during the treatment of patients with carcinomas to determine if CgA is useful as a prognostic marker in carcinomas other than prostatic cancer. Keywords: Chromogranin A, carcinoma antigens CA-15-3, CA-19-9, CA-125, carcinoembryonic antigen (CEA), prostatic specific antigen (PSA) Introduction CgA has been used to indicate neuroendocrine differentiation, which is a sign of poor prognosis.
    [Show full text]
  • Regulation of Tumor Growth by Circulating Full-Length Chromogranin A
    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 45 Research Paper Regulation of tumor growth by circulating full-length chromogranin A Flavio Curnis1,*, Alice Dallatomasina1,*, Mimma Bianco1,*, Anna Gasparri1, Angelina Sacchi1, Barbara Colombo1, Martina Fiocchi1, Laura Perani2, Massimo Venturini2, Carlo Tacchetti2, Suvajit Sen3, Ricardo Borges4, Eleonora Dondossola1, Antonio Esposito2,5, Sushil K. Mahata6 and Angelo Corti1,5 1 Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan, Italy 2 Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, Milan, Italy 3 University of California, Los Angeles, CA, USA 4 La Laguna University, Tenerife, Spain 5 Vita-Salute San Raffaele University, Milan, Italy 6 VA San Diego Healthcare System and University of California, San Diego, La Jolla, CA, USA * These authors have contributed equally to this work Correspondence to: Flavio Curnis, email: [email protected] Correspondence to: Angelo Corti, email: [email protected] Keywords: chromogranin A, angiogenesis, tumor perfusion, endothelial cells, protease-nexin-1 Received: September 9, 2016 Accepted: September 17, 2016 Published: September 24, 2016 ABSTRACT Chromogranin A (CgA), a neuroendocrine secretory protein, and its fragments are present in variable amounts in the blood of normal subjects and cancer patients. We investigated whether circulating CgA has a regulatory function in tumor biology and progression. Systemic administration of full-length CgA, but not of fragments lacking the C-terminal region, could reduce tumor growth in murine models of fibrosarcoma, mammary adenocarcinoma, Lewis lung carcinoma, and primary and metastatic melanoma, with U-shaped dose-response curves. Tumor growth inhibition was associated with reduction of microvessel density and blood flow in neoplastic tissues.
    [Show full text]